Effects of Xixin Decoction （洗心汤）-Containing Serum on BV-2 Microglial Activation and Immune Inflammation Induced by Aβ25-35
10.13288/j.11-2166/r.2025.07.011
- VernacularTitle:洗心汤含药血清对Aβ25-35诱导的BV-2小胶质细胞活化及免疫炎症的影响
- Author:
Yangyang WU
1
;
Yongchang DIWU
2
;
Chaokai YANG
1
;
Xia XING
1
;
Dengkun WANG
3
Author Information
1. First Clinical Medical College，Shaanxi University of Chinese Medicine，Xianyang，712046
2. Basic Medical College，Shaanxi University of Chinese Medicine
3. Affiliated Hospital of Shaanxi University of Chinese Medicine
- Publication Type:Journal Article
- Keywords:
Alzheimer's disease;
Xixin Decoction （洗心汤）;
immune inflammation regulation;
BV-2 cells
- From:
Journal of Traditional Chinese Medicine
2025;66(7):717-723
- CountryChina
- Language:Chinese
-
Abstract:
ObjectiveTo explore the potential mechanism of Xixin Decoction （洗心汤， XD） in treating Alzheimer's disease （AD）. MethodsXD-containing serum was prepared， and the BV-2 microglial cell viability was assessed using the CCK8 assay to determine the optimal intervention concentrations of XD-containing serum and amyloid-beta 25-35 （Aβ25-35） for subsequent experiments. BV-2 cells were divided into four groups， control group， model group （Aβ25-35）， XD-containing serum group （Aβ25-35+ XD-containing serum）， and blank serum group （Aβ25-35 + blank serum）. After 24 hours of culture， the levels of interleukin-1β（IL-1β）， cyclooxygenase-2 （COX-2）， and arginase-2 （Arg-2） in the supernatent were detected by ELISA. Immunofluorescence staining was performed to detect the protein levels of ionized calcium-binding adaptor molecule 1 （IBA1）， CD86， and CD206. RT-PCR was used to analyze the mRNA expression of IL-1β， interleukin-6 （IL-6）， and interleukin-10 （IL-10）. ResultsThe concentrations of 10% XD-containing serum and 40 μmol·L-¹ Aβ25-35 were selected for subsequent experiments. Compared to the control group， the model group showed significantly increased levels of IL-1β and COX-2 in the supernatant， as well as elevated protein expression of IBA1 and CD86 and increased mRNA expression of IL-1β and IL-6， while exhibiting significantly reduced levels of Arg-2 in the supernatant， CD206 protein expression， and IL-10 mRNA expression （P＜0.05 or P＜0.01）. Compared to the model group， the XD-containing serum group showed significant improvement in all these indicators （P＜0.01）， whereas no statistically significant differences were observed in the blank serum group （P＞0.05）. ConclusionXD may regulate microglial activation， inhibit pro-inflammatory factors， and enhance anti-inflammatory factor release， thereby improving neuroimmune inflammation and inhibiting the progression of Alzheimer's disease.
